Clincosm LogoSign in Get a demo

Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19

Sponsor
Tanta University (Other)
Overall Status
Completed
CT.gov ID
NCT04447534
Collaborator
(none)
191
Enrollment
1
Location
2
Arms
1.7
Actual Duration (Months)
109.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

we want to investigate if zinc supplementation enhance the clinical efficacy of chloroquine in treatment of COVID-19.

Condition or Disease Intervention/Treatment Phase
  • Drug: Chloroquine or hydroxychloroquine
  • Drug: zinc
 Phase 3

Detailed Description

we want to investigate if zinc supplementation enhance the clinical efficacy of chloroquine in treatment of COVID-19. As, zinc may be of value in these cases and may be of value in enhancing chloroquine effect.

Study Design

Study Type:
Interventional
Actual Enrollment :
191 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Care Provider)
Primary Purpose:
Treatment
Official Title:
Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine/Hydroxychloroquine in Treatment of COVID-19?
Actual Study Start Date :
Jun 23, 2020
Actual Primary Completion Date :
Jul 15, 2020
Actual Study Completion Date :
Aug 15, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Chloroquine or hydroxychloroquine

Chloroquine or hydroxychloroquine alone

Drug: Chloroquine or hydroxychloroquine
Chloroquine or hydroxychloroquine
Other Names:
  • alexoquine, chloroquine, hydroquine

    		•
    Experimental: Chloroquine or hydroxychloroquine with zinc

    Chloroquine or hydroxychloroquine with zinc

    Drug: Chloroquine or hydroxychloroquine
    Chloroquine or hydroxychloroquine
    Other Names:
  • alexoquine, chloroquine, hydroquine

    • Drug: zinc
    Zinc tablets

    Outcome Measures

    Primary Outcome Measures

    1. Number of patients with improvement or mortality [2 weeks]

      The number of patients with improvement or mortality.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients with positive COVID-19.
    Exclusion Criteria:
    • Contraindications or hypersensitivity to chloroquine.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Tanta university hospital, Assuit University, Ainshams University Tanta Egypt

    Sponsors and Collaborators

    • Tanta University

    Investigators

    • Principal Investigator: sherief Abd-Elsalam, Ass. Prof., ass. Prof. Tropical Medicine

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Sherief Abd-Elsalam, Ass. Prof. Tropical Medicine, Tanta University
    ClinicalTrials.gov Identifier:
    NCT04447534
    Other Study ID Numbers:
    • tanta zinc chloroquine
    First Posted:
    Jun 25, 2020
    Last Update Posted:
    Apr 1, 2022
    Last Verified:
    Mar 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Hydroxychloroquine
    Chloroquine
    Chloroquine diphosphate

    Study Results

    No Results Posted as of Apr 1, 2022